Libera Bio 

Addressing “undruggable intracellular targets” in oncology

Sector

Cancer therapeutics

Stage

Prototyping, preclinical

Country

Spain


Only technology delivering whole mAbs to intracellular targets

Versatile actively-targeted nanocapsules from approved materials

Lead compound shows results with KRAS. Abundant data from POP and POC with multiple small molecules and mAbs

This information is confidential, do not share or copy.

You can visit their website or

Download the Pitch Deck
Other files:

Transactions 180205 Comparable Transactions v2_3oj

Transactions Licensing Trends 201216_170516 (1)

Libera Bio 2-pager

Market Information A2.1

Market Information A2.2

Market Information A2.3

Market Information A2.4

Market Information A2.5

Market Information A2.6

Market Information A2.7

Market Information A2.8

Libera Bio Publications (1)

Libera Bio Publications (2)

181000 (Inivo investment trends in immuno-oncology) IV1810_Outcome-Capital_Final_LRS

180601 (IQVIA) Global Oncology Trends 2018

Under evaluation at least till: 14th October

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar